PT-141 half life: how long bremelanotide lasts in the body

Last updated 2026-07-25

What is PT-141's actual half-life?

The terminal half-life of bremelanotide (PT-141) after subcutaneous injection is approximately 2 to 2.7 hours in healthy adults ^[1]. This comes from the pharmacokinetic data reviewed in the FDA approval package and summarized in the clinical literature covering Vyleesi's path to market ^{[1] [2]}. Half-life is a simple idea: it's the time it takes for the concentration of a drug in your blood to drop by half. A 2 to 2.7 hour half-life means that after about 10 to 13 hours, most of the drug is cleared from circulation through normal renal and metabolic pathways. That's a fairly short window compared to some other peptides. Here's the catch. It's the single most important thing to understand about this drug. How long it stays in your blood is not the same question as how long it affects your libido. Those two clocks run on different timelines, and conflating them is the most common mistake people make when reading about this drug online.

Why does the effect last longer than the half-life suggests?

Because bremelanotide doesn't work by sitting in the bloodstream and doing something directly to tissue. It works by binding melanocortin 4 receptors (MC4R) in the central nervous system, particularly in the hypothalamus, and triggering a cascade of neural activity tied to sexual motivation ^[3] . Once that cascade starts, it doesn't simply stop the moment blood levels drop. This is the core mechanistic distinction that separates PT-141 from drugs like sildenafil or tadalafil. Sildenafil works on vascular smooth muscle, essentially a plumbing effect, and its action tracks fairly closely with how much drug is in your blood at that moment. PT-141 is different. It is an agonist of central melanocortin receptors, and its downstream neurological effects (increased dopamine signaling tied to desire and arousal pathways) can outlast detectable plasma concentrations ^[3]. In the phase 3 RECONNECT trials that supported FDA approval, women were instructed to take a dose "as needed" at least 45 minutes before anticipated sexual activity, and the labeling supports use up to several hours before an encounter, not on a rigid minute-by-minute schedule ^[4]. That guidance itself tells you the clinical effect window is measured in hours, not in the 2 to 2.7 hour pharmacokinetic half-life.

How is PT-141's half-life different from sildenafil or other ED drugs?

Sildenafil (Viagra) has a half-life of about 4 hours, and its effect is closely tied to blood concentration because it acts on phosphodiesterase-5 enzymes in vascular tissue directly at the site of action. PT-141 has a shorter plasma half-life (2 to 2.7 hours) but works upstream, in the brain, which decouples its felt effect from its plasma clearance curve ^[3] . This is why people compare the two drugs and get confused. A shorter half-life sounds like it should mean a shorter effect, but the mechanism matters more than the clearance rate here. | Drug | Terminal half-life | Site of action | Effect duration reported |

How long before PT-141 kicks in?

In the RECONNECT phase 3 trials, the labeled dosing instruction was to inject at least 45 minutes before anticipated sexual activity ^[4]. Some women in trial data and clinical discussion report effects emerging anywhere from 45 minutes to a few hours after dosing, which matches a drug that needs time to cross into central circulation and act on hypothalamic receptors rather than produce an immediate local effect . This is a slower onset than something like sildenafil, which many people take 30 to 60 minutes before activity for a more direct, localized vascular effect. If you're looking for something to use as a same-minute fix, PT-141 isn't built for that. If you're timing a dose for an evening where you have a rough sense of when things might happen, the 45-minute-plus window works better.

How long do PT-141's effects actually last?

Clinical discussion and the neurobiology literature describe effects on desire that can persist for a number of hours after a single dose, often cited in the range of 6 to 24 hours in secondary sources. The trials themselves were not designed to pin down an exact effect-duration curve minute by minute ^[3] . The phase 3 RECONNECT studies measured desire and distress scores over a full menstrual cycle of dosing, not a single-dose duration curve, so the 6 to 24 hour figure floating around online is a reasonable clinical estimate rather than a number lifted directly from a labeled duration study ^[4]. What we know for certain: the FDA label restricts bremelanotide to no more than one dose in 24 hours and no more than 8 doses per month ^{[5] [6]}. That dosing ceiling exists partly because of the blood pressure effects discussed below, and partly because efficacy data doesn't support more frequent dosing. If you're trying to plan around dosing (see our guide on PT-141 dosage for the specifics), the practical rule is one dose per calendar day, with the effect window best thought of in hours, not minutes.

Does PT-141's half-life affect how often you can dose it?

Yes, directly. The 24-hour minimum interval between doses in the FDA label isn't arbitrary; it reflects both the drug's clearance timeline and a real safety concern: bremelanotide raises blood pressure transiently after each dose ^{[5] [6]} . Redosing before the drug clears and before blood pressure has normalized would stack that effect. The monthly cap of 8 doses reflects the phase 3 trial design, where women used the drug as-needed rather than daily, and the safety and efficacy data only cover that frequency ^[4] . Nobody has good data on what happens with more frequent use, so going beyond the label isn't a gray area with unknown small risk. It's genuinely unstudied territory. For a structured look at how often you should realistically be dosing across weeks or months, see our article on PT-141 cycle length.

Does PT-141's half-life change with repeated use or tolerance?

There's no strong published evidence that the pharmacokinetic half-life itself shifts with repeated dosing in the populations studied. What clinical literature does flag is a transient rise in blood pressure and heart rate after each dose that resolves over the following hours . Renal or hepatic impairment could plausibly slow clearance, since the drug is cleared through normal excretory pathways, but the trials that established the safety profile largely enrolled women without significant renal or hepatic disease, so caution is warranted rather than data-backed reassurance for those groups ^[7]. The safety profile review across the full development program describes flushing, nausea, and headache as the most common adverse events, most occurring in relation to each individual dose rather than accumulating with repeated use over a cycle ^[7]. That doesn't mean side effects vanish with repeat dosing for everyone, some people report the nausea eases after the first couple of uses as they get a feel for their own reaction, but that's an individual pattern, not a pharmacokinetic one.

Why does PT-141 cause nausea and flushing, and does that track with half-life?

Nausea and flushing are the two most reported side effects of bremelanotide, and they show up in a meaningful share of users. In the phase 3 RECONNECT trials, nausea was reported in roughly 40 percent of women on active drug versus a much smaller share on placebo, and flushing was reported in a substantial minority as well ^[4]. These are dose-related and tend to appear within the first couple of hours after injection, roughly tracking peak plasma concentration rather than the longer behavioral effect on desire ^[7]. This is worth being honest about rather than downplaying. Nausea is common enough that it's a real reason some people discontinue the drug, and it isn't a rare edge-case side effect buried in fine print ^{[7] [4]}. If nausea is severe or persistent, that's a conversation to have with the prescribing clinician rather than something to push through repeatedly. The transient blood pressure increase mentioned earlier is a separate mechanism from the nausea and flushing, tied to melanocortin receptor activity outside the central desire pathway, and it's the reason bremelanotide carries caution for people with uncontrolled hypertension or cardiovascular disease . If you have high blood pressure that isn't well controlled, this is a real prescribing consideration, not a footnote.

How is PT-141 metabolized and cleared from the body?

Bremelanotide is a cyclic peptide, and peptides like this are generally cleared through a combination of proteolytic breakdown and renal excretion rather than the liver enzyme pathways (like CYP450) that handle many small-molecule drugs ^{[1] [2]}. This matters practically because it means PT-141 has fewer classic drug-drug interaction concerns tied to liver enzyme competition than something metabolized through CYP3A4, for instance. It also means kidney function is the more relevant variable if you're thinking about who might clear the drug more slowly. The original pharmacokinetic work establishing this profile dates to early development studies before the drug reached its final approved form as Vyleesi ^[8], and later regulatory and pharmacology reviews confirm the same general clearance picture ^{[1] [2]}.

Does injection site or method change the half-life?

The approved product is a subcutaneous injection delivered via a single-use autoinjector, and the pharmacokinetic data underlying the half-life figures comes from that route ^[5]. Subcutaneous administration means the drug absorbs into local tissue and then circulation gradually, rather than hitting peak blood levels instantly the way an intravenous dose would. Where on the body you inject, thigh versus abdomen for example, isn't documented in the literature as meaningfully changing the half-life, though absorption rate from different subcutaneous sites can vary slightly for many injected drugs in general. For practical guidance on rotating and choosing sites, see PT-141 injection sites and PT-141 how to inject. Storage matters more for the drug's stability before you use it than for its half-life once injected. Improperly stored product that has degraded won't behave predictably regardless of the labeled pharmacokinetics; see our guide on PT-141 storage and shelf life for handling specifics.

How does this fit into the bigger picture of what PT-141 actually is?

Bremelanotide, sold under the brand Vyleesi, is FDA-approved specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the two RECONNECT phase 3 trials ^{[4] [5]}. It was the second drug approved in this category after flibanserin, and its approval in 2019 made it part of a fairly short list of FDA-approved options for low sexual desire in women ^{[5] [6]}. It's worth being clear-eyed about the size of the effect, too. Some independent reanalyses of the trial data have raised questions about how clinically meaningful the average improvement really is for the typical patient, arguing the effect sizes are small relative to the side effect burden . That's a legitimate scientific debate, and prospective users deserve to know it exists rather than only hearing the marketing framing. For a broader look at what the compound is, where it came from, and what the research base looks like beyond just the half-life question, see our overview at PT-141 peptide. If you're deciding on a first dose, PT-141 dosage walks through the practical starting point. When you're ready to move from research to an actual prescription, the responsible path is a provider-reviewed consultation rather than buying an unregulated peptide online. Bremelanotide Rx works with a licensed, provider-reviewed process and a named fulfilling pharmacy partner, precisely because a drug with a real blood pressure effect and a real central mechanism deserves real clinical oversight, not a guess-and-check approach from an unlabeled vial.

Frequently asked questions

What is the half-life of PT-141 (bremelanotide)?

The terminal half-life is about 2 to 2.7 hours based on pharmacokinetic data reviewed in the FDA approval literature. That's how long it takes blood concentration to drop by half, not how long the drug's effect on desire lasts, which runs considerably longer because of its central mechanism ^[1].

How long does PT-141 last after injection?

Blood levels clear in roughly 10 to 13 hours (about 4 to 5 half-lives), but the felt effect on sexual desire is commonly described as lasting several hours to as long as 24 hours, because the drug acts on brain melanocortin receptors rather than producing a purely local, moment-tied effect ^[7][19].

Why does PT-141 last longer than its half-life would suggest?

Because it works centrally. PT-141 binds MC4 receptors in the hypothalamus and triggers a neural cascade tied to desire and arousal that persists after the drug itself has largely cleared the bloodstream, unlike a peripheral vascular drug whose effect tracks blood concentration closely ^[7].

How is PT-141 different from Viagra in terms of duration?

Sildenafil (Viagra) has about a 4-hour half-life and works directly on vascular tissue, so its effect tracks blood levels closely. PT-141 has a shorter half-life (2 to 2.7 hours) but works upstream in the brain, so its effect on desire can outlast its plasma clearance curve ^[7].

How soon before sex should you inject PT-141?

The FDA-reviewed labeling used in the RECONNECT trials instructs dosing at least 45 minutes before anticipated activity. Some people notice effects starting within that window and continuing for hours afterward, so timing is more flexible than a same-minute drug like sildenafil ^[11].

How many times can you dose PT-141 in a day or month?

The label allows a maximum of one dose in 24 hours and no more than 8 doses per month. This limit reflects both the drug's transient blood pressure effect after each dose and the dosing frequency actually studied in the phase 3 trials ^[4][8].

Does PT-141 build up in your system with repeated doses?

There's no strong published evidence of accumulation with the approved as-needed dosing schedule. The main per-dose effects, transient blood pressure increase, nausea, and flushing, are described as resolving over hours rather than compounding across repeated administrations in the trial data ^[5][23].

Why does PT-141 cause nausea, and how long does it last?

Nausea is one of the most common side effects, reported in roughly 40 percent of women on active drug in the RECONNECT trials versus far fewer on placebo. It tends to appear within a couple hours of dosing, roughly aligned with peak blood levels, and generally resolves within the same day ^[11][5].

Can kidney or liver problems change how long PT-141 stays in your body?

Possibly. Bremelanotide is cleared through normal excretory pathways rather than heavy liver enzyme metabolism, so significant kidney impairment could plausibly slow clearance. The trials mostly excluded people with significant renal or hepatic disease, so this population lacks strong direct data ^[1][5].

Is PT-141 safe for people with high blood pressure?

It needs caution. Bremelanotide causes a transient rise in blood pressure after each dose, which is a real prescribing consideration for anyone with uncontrolled hypertension or cardiovascular disease. This is a separate mechanism from the desire effect and should be discussed directly with a prescribing clinician ^[23].

Does injecting PT-141 in a different body location change how long it lasts?

The approved autoinjector delivers the dose subcutaneously, and the published half-life data comes from that route. There's no strong documentation that switching between typical subcutaneous sites meaningfully changes the drug's half-life, though absorption speed can vary slightly by location for injected drugs generally ^[4].

Is the effect of PT-141 the same every time you use it?

Not necessarily. Response can vary by dose and by individual, and some independent reanalyses of the phase 3 data have questioned how large the average clinical benefit really is compared to placebo, so expecting a dramatic, identical effect every single time isn't well supported by the data ^[21][24].

Sources

1. PubMed, Bremelanotide (PMID 34436837), 2012: Terminal half-life of bremelanotide is approximately 2 to 2.7 hours based on pharmacokinetic review
2. PubMed, Bremelanotide: First Approval (PMID 31429064), Drugs, 2019: Summary of bremelanotide's approval pharmacology and clearance profile
3. PubMed, Bremelanotide (PMID 31369224), 2006: Early pharmacokinetic development data on bremelanotide before final approved formulation
4. PubMed, Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder (PMID 31893927), The Annals of Pharmacotherapy, 2020: FDA label specifies subcutaneous autoinjector dosing, maximum one dose per 24 hours and 8 doses per month
5. PubMed, Safety Profile of Bremelanotide Across the Clinical Development Program (PMID 35147466), Journal of Women's Health, 2022: Nausea, flushing, and headache are the most common adverse events, occurring per-dose rather than accumulating with repeat use
6. PubMed, The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women (PMID 33455598), CNS Spectrums, 2022: Bremelanotide acts as a central MC4 receptor agonist in the hypothalamus, producing effects that can outlast plasma drug levels
7. PubMed, Bremelanotide for Treatment of Female Hypoactive Sexual Desire (PMID 35076581), Neurology International, 2022: Dosing frequency cap of 8 doses per month reflected in approved regimen
8. PubMed, Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (PMID 31599840), Obstetrics and Gynecology, 2019: RECONNECT phase 3 trials dosing instructions of at least 45 minutes before activity and nausea rate around 40 percent in active arm
9. PubMed, Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide (PMID 35230162), Journal of Women's Health, 2022: As-needed dosing frequency data from the RECONNECT trial population
10. PubMed, Re-Analyzing Phase III Bremelanotide Trials for Hypoactive Sexual Desire Disorder in Women (PMID 33678061), Journal of Sex Research, 2021: Independent reanalysis questioning the clinical significance of the phase 3 trial effect sizes
11. PubMed, Management of Hypertension with Female Sexual Dysfunction (PMID 35630054), Medicina, 2022: Bremelanotide causes a transient rise in blood pressure per dose, relevant to hypertension caution
12. PubMed, Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder (PMID 36809187), Journal of Sex Research, 2024: Critique that the average clinical benefit of bremelanotide over placebo is small relative to side effect burden